Application of interventional therapy on hepatocellular carcinoma with hepatic arterioportal shunts
10.3760/cma.j.issn.1673-4904.2011.26.012
- VernacularTitle:介入治疗在肝细胞癌伴肝动脉-门静脉分流患者中的应用
- Author:
Shunji SUN
;
Gang HAO
;
Kai ZHAO
;
Shuai WANG
;
Xueqiang FENG
;
Peng WANG
;
Xiuchun WANG
- Publication Type:Journal Article
- Keywords:
Liver neoplasms;
Arterioportal shunts;
Interventional therapy
- From:
Chinese Journal of Postgraduates of Medicine
2011;34(26):30-32
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo observe the clinical effect of interventional embolization on hepatocellular carcinoma(HCC) with hepatic arterioportal shunts(APS) ,in the hope of improving patients' survival quality and time. MethodsTwenty-nine patients with HCC patients and APS after a successful PVA,steel coils embolization, all patients were given routine TACE therapy. The changes of gastrointestinal bleeding,ascites,diarrhea and aminotransferase were analyzed retrospectively. ResultsNineteen cases got successful embolization in the first time[achievement ratio 65.5％(19/29)]; 3 cases got recurrence after embolization [patency ratio 10.3％(3/29)],7 cases appeared new APS[incidence ratio 24.1％(7/29),5 cases were embolized 2 times, 2 cases were embolized 3 times]. The effective rate of gastrointestinal bleeding,diarrhoea,aacites were 91.7％ (11/12), 84.6％ ( 11/13 ), 83.3％ ( 15/18 ) respectively, which had significant difference between preoperative and postoperative condition. The survival rate of 3 months,6 months, 1 year,and 2 years after operation were 96.6％ (28/29),89.7％ (26/29),65.5％ (19/29),34.5％ (10/29). Conclusion Interventional therapy is a safe and effective treatment to HCC with APS.
